Article info
PDFClinical and epidemiological research
Extended report
Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?
- Correspondence to Dr A Strangfeld, Programmbereich Epidemiologie, Deutsches Rheuma-Forschungszentrum Berlin, ein Leibniz Institut, Charitéplatz 1, 10117 Berlin, Germany; strangfeld{at}drfz.de
Citation
Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?
Publication history
- Accepted June 13, 2011
- First published July 25, 2011.
Online issue publication
April 09, 2023
Article Versions
- Previous version (25 October 2017).
- You are viewing the most recent version of this article.
Web Only Data
Files in this Data Supplement:
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This paper is freely available online under the BMJ Journals unlocked scheme, see http://ard.bmj.com/info/unlocked.dtl